Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
China · Delayed Price · Currency is CNY 62.15
0.00 (0.00%)
Feb 2, 2026, 4:00 PM EST
SHE:301075 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 176.4 | 239.92 | 333.67 | 400.98 | 529.62 | 490.16 |
Other Revenue | 0.71 | 0.71 | 0.63 | 0.07 | - | - |
| 177.11 | 240.63 | 334.3 | 401.05 | 529.62 | 490.16 | |
Revenue Growth (YoY) | -38.63% | -28.02% | -16.64% | -24.27% | 8.05% | 9.06% |
Cost of Revenue | 160.68 | 148.82 | 106.19 | 92.68 | 60.43 | 44.5 |
Gross Profit | 16.43 | 91.8 | 228.11 | 308.37 | 469.19 | 445.67 |
Selling, General & Admin | 98.52 | 135.04 | 202.13 | 272.76 | 374.79 | 349.37 |
Research & Development | 59.62 | 37 | 24 | 26.45 | 24.07 | 23.35 |
Other Operating Expenses | -3.43 | 1.93 | 3.71 | 4.64 | 6.59 | 6.24 |
Operating Expenses | 159.95 | 179.62 | 230.68 | 306.56 | 406.8 | 379.86 |
Operating Income | -143.52 | -87.81 | -2.57 | 1.81 | 62.38 | 65.81 |
Interest Expense | -3.63 | -7.9 | -3.11 | -1.36 | -1.18 | -1.97 |
Interest & Investment Income | 1.86 | 10.07 | 13.36 | 9.3 | 1.16 | 0.24 |
Other Non Operating Income (Expenses) | -25.23 | -1.74 | 1.71 | -0.2 | -0.07 | -0.56 |
EBT Excluding Unusual Items | -170.52 | -87.39 | 9.39 | 9.55 | 62.3 | 63.52 |
Impairment of Goodwill | -0.23 | -0.23 | -0 | - | - | - |
Gain (Loss) on Sale of Investments | -0.05 | 0.54 | 0.07 | - | -0.2 | - |
Gain (Loss) on Sale of Assets | 0.03 | 0.04 | 0.08 | - | - | -0.79 |
Asset Writedown | -1.64 | -0.05 | -0.01 | -0.01 | -0 | -0 |
Other Unusual Items | 1.67 | 1.31 | 12.72 | 11.48 | 11.18 | 38.28 |
Pretax Income | -170.74 | -85.77 | 22.25 | 21.02 | 73.28 | 101.02 |
Income Tax Expense | 0.43 | -0.75 | 5.16 | 2.44 | 7.42 | 11.4 |
Earnings From Continuing Operations | -171.17 | -85.03 | 17.09 | 18.58 | 65.86 | 89.61 |
Minority Interest in Earnings | 45.85 | 22.36 | 1.76 | 1.92 | 2.65 | 2.37 |
Net Income | -125.32 | -62.67 | 18.85 | 20.5 | 68.51 | 91.99 |
Net Income to Common | -125.32 | -62.67 | 18.85 | 20.5 | 68.51 | 91.99 |
Net Income Growth | - | - | -8.05% | -70.07% | -25.53% | 28.29% |
Shares Outstanding (Basic) | 78 | 79 | 79 | 79 | 65 | 60 |
Shares Outstanding (Diluted) | 78 | 79 | 79 | 79 | 65 | 60 |
Shares Change (YoY) | -1.83% | 0.99% | -0.39% | 20.86% | 8.52% | - |
EPS (Basic) | -1.61 | -0.79 | 0.24 | 0.26 | 1.05 | 1.53 |
EPS (Diluted) | -1.61 | -0.79 | 0.24 | 0.26 | 1.05 | 1.53 |
EPS Growth | - | - | -7.69% | -75.24% | -31.37% | - |
Free Cash Flow | -156.15 | -108.09 | -11.28 | -31.6 | 42.8 | 12.82 |
Free Cash Flow Per Share | -2.01 | -1.36 | -0.14 | -0.40 | 0.66 | 0.21 |
Dividend Per Share | - | - | 0.125 | - | 0.625 | - |
Gross Margin | 9.28% | 38.15% | 68.24% | 76.89% | 88.59% | 90.92% |
Operating Margin | -81.03% | -36.49% | -0.77% | 0.45% | 11.78% | 13.43% |
Profit Margin | -70.76% | -26.04% | 5.64% | 5.11% | 12.93% | 18.77% |
Free Cash Flow Margin | -88.17% | -44.92% | -3.37% | -7.88% | 8.08% | 2.61% |
EBITDA | -110.51 | -61.1 | 15.76 | 16.44 | 76.07 | 77.94 |
EBITDA Margin | -62.40% | -25.39% | 4.71% | 4.10% | 14.36% | 15.90% |
D&A For EBITDA | 33.01 | 26.72 | 18.33 | 14.63 | 13.68 | 12.13 |
EBIT | -143.52 | -87.81 | -2.57 | 1.81 | 62.38 | 65.81 |
EBIT Margin | -81.03% | -36.49% | -0.77% | 0.45% | 11.78% | 13.43% |
Effective Tax Rate | - | - | 23.18% | 11.61% | 10.12% | 11.29% |
Revenue as Reported | 40.11 | 240.63 | 334.3 | 401.05 | 529.62 | 490.16 |
Advertising Expenses | - | 62.61 | 145.61 | 217.83 | 315.11 | 295.61 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.